Vera Therapeutics
Logotype for Vera Therapeutics Inc

Vera Therapeutics (VERA) investor relations material

Vera Therapeutics 44th Annual J.P. Morgan Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Vera Therapeutics Inc
44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026

Strategic outlook and pipeline

  • Preparing for commercial launch of lead candidate atacicept in IgAN with FDA priority review and PDUFA date set for July 7, 2026.

  • Pipeline includes MAU868 (phase II, BK virus) and VT-109 (preclinical, immune modulation), with full ownership across all indications and geographies.

  • Strong financial position with $779 million pro forma cash and access to $425 million in non-dilutive capital.

  • Management team has deep experience in clinical development and commercialization.

Clinical development and efficacy data

  • Atacicept demonstrated statistically significant reduction in proteinuria and robust efficacy across subgroups in phase III IgAN trial.

  • Safety profile similar to placebo, with low rates of serious adverse events and high patient retention over two years.

  • Long-term eGFR data to be shared in early 2027; ongoing trials (PIONEER, Extend) will provide additional data in broader patient populations.

  • Atacicept is self-administered weekly via autoinjector, with high desirability among nephrologists.

Market opportunity and commercialization plans

  • U.S. IgAN patient population estimated at 160,000, with half at high risk; new guidelines support earlier intervention.

  • Commercial team and sales force of 82 reps being hired to target over half of 11,000 U.S. nephrologists.

  • Disease state awareness and education efforts have been ongoing for years, with strong recognition among nephrologists.

  • Atacicept positioned as a category-creating launch with potential for premium pricing and broad payer coverage.

How to sustain atacicept's eGFR advantage long-term
Assess monthly atacicept's strategic market impact
Prioritize atacicept's non-IgAN expansion strategy
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Vera Therapeutics earnings date

Logotype for Vera Therapeutics Inc
Q4 202524 Mar, 2026
Vera Therapeutics
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Vera Therapeutics earnings date

Logotype for Vera Therapeutics Inc
Q4 202524 Mar, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Vera Therapeutics, Inc. is a clinical-stage biotechnology company engaged in developing and commercializing treatments aimed at serious immunological diseases. Their portfolio includes atacicept, a fusion protein undergoing clinical trials for immunoglobulin A nephropathy and Phase II trials for lupus nephritis. Another significant development in their pipeline is MAU868, a monoclonal antibody targeting the BK virus in transplant patients. The company is headquartered in Brisbane, California, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage